Allergy

Autoimmune Diseases

Biosimilars

COVID-19

Cannabidiol (CBD)

Cardiology

Compounding

Continuous Glucose Monitoring

Dermatology

Diabetes

Digestive Health

Endocrinology

Eye Health

Generics

Headache and Migraine

Immunization

Infectious Disease

Influenza

Medical Devices

Mental and Behavioral Health

Neurology

Oncology

Pain Management

Pediatrics

Public Health

Rare Diseases

Respiratory

Rheumatology

Shingles

Substance Use Disorder

Technology and Data

Veterinary Pharmacy 

Women's Health

News

FDA Updates

Law and Advocacy

Technology Trends

Viewpoints

All News

Media

Around the Practice

In-Depth Insights

K-Casts

Script-Ed

Expert Interviews

Podcasts

Conferences

Conference Coverage

Conference Listing

Resources

Disease Awareness 

CME/CE

Partners

Publications

Drug Topics Journal

Total Pharmacy Journal

Events

Virtual Events

Total Pharmacy Solutions Summit

Business

Business Strategies

Patient Services

Pharmacy Inventory

Law and Regulations

All Business News

Practice Type

Independent Pharmacy

Chain Pharmacy

Specialty Pharmacy

Health System Pharmacy

Pharmacy Technicians

Subscribe

Articles

By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.

Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.

Smell Loss Still Impacted Some Patients 1 Year After COVID-19 Diagnosis

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

FDA Issues CRL for Epidermolysis Bullosa Gene Therapy

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Drug Topics

Facebook

Twitter

LinkedIn

Spotlight

How to strengthen your team’s role as a trusted clinical advisor

IDWeek

Important Steps You Need To Take Before Choosing A Pharmacy Software Vendor: Not All Review Sites Are Created Equal

Improving Care For Every Patient

Protecting Public Health Through Quality in Vaccine Inventory Storage

NCPA

Optimizing Treatment Strategies for Diabetes

Proper Injection Technique Ensures Positive Outcomes Among Patients With Diabetes

Special Report: Pharmacy Finances

The Evolving Landscape of Influenza Immunizations

The Power of Community: Pharmacists Share Their Experiences With Service Expansion

Rethink Medication Adherence With Sustainable Multidose Packaging

1rem

Authors

Joseph P. Nathan, PharmD, MS

Articles